Introducing Lebrikizumab for AD
Leigh Ann Pansch, MSN, FNP-BC, DCNP, Clinical Director of Education at DOCS Dermatology in Cincinnati, OH, shares her enthusiasm about the recent approval of lebrikizumab-lbkz (Ebglyss, Lilly) for adults and children aged 12 and older with moderate to severe atopic dermatitis (AD).